Browse by Track

7: Circulating B cells subpopulations and outcomes to Checkpoint Blockade in patients with renal cell carcinoma.

8: Understand the Biology of Kidney Cancer Progression

9: Characterisation of HIF-mediated genoprotection in clear cell renal cell carcinoma

10: The use of Renal tumor biopsies (RBx) has increased at Haukeland University Hospital(HUS) during 2008-2022

11: Correlation of PSMA expression on [18F]PSMA-1007 PET with morphological changes in patients with metastatic renal cell cancer undergoing tyrosine kinase and checkpoint inhibitor therapy

6: 2022 Global Patient Survey: Reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas

38: REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): a multi-arm phase II trial testing reduced intensity immunotherapy across different cancers

Oral Abstract: Patients’ experiences on the course of treatment after partial nephrectomy or percutaneous cryoablation of small renal cell carcinoma - a cross-sectional multicenter study

12: T-Rex Study: Real-world evidence and patient-reported outcomes of mRCC patients treated first-line with tivozanib

13: Active Surveillance for Small Renal Masses: Living with an potential untreated cancer

14: Exploring the perspectives of patients with localised kidney cancer on their treatment decisions: a qualitative study

15: Patient experience of follow-up after surgery for kidney cancer: a focus group study

16: Clinical Outcome of Patients with Primary Metastatic Renal Cell Carcinoma Carefully Selected for Cytoreductive Nephrectomy: A Nationwide Real-World Data

17: Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma (RCC) in England

18: Optimal Duration of Frontline Immunotherapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)

19: Real World Experience (RWE) of Ipilimumab and Nivolumab compared to Pembrolizumab and Axitinib in Advanced Renal Cell Carcinoma (RCC)

20: A UK real-world observational study of avelumab + axitinib (A+Ax) in advanced renal cell carcinoma (RCC): exploratory analysis of 24-month interim results in patients with non-clear cell histology

21: Real-world recurrence patterns in Danish renal cell carcinoma patients

22: Baseline characteristics from the real-world CARINA study of patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy

23: Role of cytoreductive nephrectomy in metastatic RCC, single institution experience

24: Real-world outcomes of nivolumab (NIVO) + ipilimumab (IPI) in patients with previously untreated clear cell advanced renal cell carcinoma (aRCC) in France.

25: 4-weekly avelumab administration plus axitinib in patients with metastatic renal cell carcinoma: A single centre analysis of patient outcomes

26: Anticoagulant treatment and thromboembolic events prior to diagnosis of renal cell carcinoma: Impact on stage distribution

35: Renal cell carcinoma and therapeutic opportunities in the paradigm shift – a case report

36: Long survivorship in metastatic kidney cancer during targeted-therapy era

32: Clinical benefit of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after checkpoint inhibitor (CPI) therapy: interim results from the Phase 2 CaboPoint trial

29: Efficacity and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: a retrospective multicentric study

30: Association of ABO blood type with toxicity and response to immunotherapy in metastatic renal cell carcinoma (mRCC)

31: Efficacy of immune checkpoint inhibitor (ICI) combination therapy as first-line (1L) treatment in metastatic renal cell carcinoma (mRCC).

27: Immune-related adverse events after ≥12 months of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma

28: Real world experience of managing immunotherapy toxicity at a UK tertiary centre

Oral Abstract: Eosinophilic solid and cystic renal cell carcinoma : a rare new entity associated with TSC1/TSC2 genetic alteration and rare metastatic potential.

33: Investigating response to Axitinib in Kidney Cancer with Venous Tumour Thrombus: translational analysis of the NAXIVA Trial

34: Baseline cytokine levels according to IMDC score in patients with metastatic clear cell renal cell carcinoma treated with nivolumab in the NIVOREN GETUG-AFU 26 Translational study

37: The metanephric adenoma - a benign variant of the Wilms' tumor: case report of an extremely rare kidney tumor